New treatment options for Bartter's syndrome.
Kleta
R
R
Basoglu
C
C
Kuwertz-Bröking
E
E
D001477:Bartter Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D002675:Child, Preschool; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000627:therapeutic use*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D012982:Sodium, Dietary; D013450:Sulfones
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D012982:Sodium, Dietary; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases